An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
Rosen
G
G
D000141:Acidosis, Renal Tubular / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D015080:Mesna / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012516:Osteosarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D011182:Postoperative Care; D011300:Preoperative Care; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D016879:Salvage Therapy; D013794:Thallium Radioisotopes; D016896:Treatment Outcome
D013794:Thallium Radioisotopes; D004317:Doxorubicin; D015080:Mesna; D002945:Cisplatin; D002955:Leucovorin; D007069:Ifosfamide; D008727:Methotrexate